These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8863137)

  • 21. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited sampling model for area under the concentration time curve of total topotecan.
    Minami H; Beijnen JH; Verweij J; Ratain MJ
    Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer.
    Asai G; Yamamoto N; Toi M; Shin E; Nishiyama K; Sekine T; Nomura Y; Takashima S; Kimura M; Tominaga T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):468-72. PubMed ID: 12107551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
    Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
    Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
    Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
    Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
    Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
    J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling multi-drug chemotherapy: tailoring treatment to individuals.
    Gardner SN
    J Theor Biol; 2002 Jan; 214(2):181-207. PubMed ID: 11812172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
    Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.
    Sadzuka Y; Sugiyama T; Suzuki H; Sawanishi H; Miyamoto K
    Toxicol Lett; 2004 May; 150(3):341-9. PubMed ID: 15110086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.
    Gourdeau H; McAlpine JB; Ranger M; Simard B; Berger F; Beaudry F; Farnet CM; Falardeau P
    Cancer Chemother Pharmacol; 2008 May; 61(6):911-21. PubMed ID: 17622531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronopharmacology and chronotherapy of cancers].
    Lévi F
    Pathol Biol (Paris); 1996 Sep; 44(7):631-44. PubMed ID: 8977920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.
    Fuse E; Kobayashi S; Inaba M; Suzuki H; Sugiyama Y
    J Natl Cancer Inst; 1994 Jul; 86(13):989-96. PubMed ID: 8024657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug.
    Terranova N; Magni P
    Comput Methods Programs Biomed; 2012 Feb; 105(2):162-74. PubMed ID: 22005012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Availability evaluation of closed systems by using practical training kits for preparation of antitumor drugs].
    Sato J; Odagiri N; Terui K; Iwasaki Y; Hosoya E; Hayakari M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1753-7. PubMed ID: 20841940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving drug penetration to curb tumor drug resistance.
    Marcucci F; Corti A
    Drug Discov Today; 2012 Oct; 17(19-20):1139-46. PubMed ID: 22706017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational pharmacokinetic rationale for intra-arterial delivery to the brain.
    Cooke JN; Ellis JA; Hossain S; Nguyen J; Bruce JN; Joshi S
    Drug Deliv Transl Res; 2016 Oct; 6(5):622-9. PubMed ID: 27431401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.